PKO Investment Management Joint Stock Co Boosts Stake in Gilead Sciences, Inc. $GILD

PKO Investment Management Joint Stock Co raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 322.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 38,000 shares of the biopharmaceutical company’s stock after purchasing an additional 29,000 shares during the quarter. PKO Investment Management Joint Stock Co’s holdings in Gilead Sciences were worth $4,218,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. GoalVest Advisory LLC raised its holdings in shares of Gilead Sciences by 7,566.7% in the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 227 shares during the period. Corundum Trust Company INC acquired a new position in Gilead Sciences in the 3rd quarter valued at about $26,000. Harbor Asset Planning Inc. acquired a new position in Gilead Sciences in the 2nd quarter valued at about $27,000. Howard Hughes Medical Institute acquired a new stake in shares of Gilead Sciences during the second quarter worth about $30,000. Finally, Putney Financial Group LLC boosted its stake in shares of Gilead Sciences by 53.4% in the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 94 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. TD Cowen boosted their target price on Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a report on Thursday, October 23rd. UBS Group started coverage on Gilead Sciences in a report on Wednesday, January 7th. They issued a “buy” rating and a $145.00 price objective for the company. HSBC lifted their target price on shares of Gilead Sciences from $110.00 to $133.00 and gave the company a “hold” rating in a report on Wednesday, December 10th. Truist Financial assumed coverage on shares of Gilead Sciences in a research note on Monday, November 24th. They set a “buy” rating and a $140.00 price target for the company. Finally, BMO Capital Markets set a $135.00 price objective on shares of Gilead Sciences in a research report on Tuesday, November 25th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $133.20.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $122.60 on Tuesday. The firm has a market cap of $152.11 billion, a price-to-earnings ratio of 19.01, a price-to-earnings-growth ratio of 0.64 and a beta of 0.33. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. Gilead Sciences, Inc. has a 1-year low of $89.02 and a 1-year high of $128.70. The firm’s fifty day moving average price is $123.28 and its 200 day moving average price is $117.77.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The firm had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. During the same period in the prior year, the company posted $2.02 earnings per share. The firm’s revenue for the quarter was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th were paid a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date of this dividend was Monday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is 48.99%.

Insider Activity

In related news, EVP Deborah H. Telman sold 53,646 shares of Gilead Sciences stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $122.85, for a total transaction of $6,590,411.10. Following the completion of the sale, the executive vice president owned 43,676 shares in the company, valued at approximately $5,365,596.60. This trade represents a 55.12% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $125.86, for a total transaction of $3,524,080.00. Following the completion of the transaction, the insider owned 107,193 shares in the company, valued at approximately $13,491,310.98. This trade represents a 20.71% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 136,257 shares of company stock worth $16,855,192. 0.27% of the stock is owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.